Highest-materiality recent filing
DexCom sets 10%+ annual organic revenue growth target through 2030; authorizes $1B share buyback
Long-range target: organic revenue growth 10%+ every year through 2030.
Dexcom Q1 revenue $1.19B (+15% YoY), EPS $0.51; raises margin guidance
Q1 revenue $1.192B (+15% YoY); GAAP diluted EPS $0.51, non-GAAP $0.56.
Kevin Sayer returns as DexCom Executive Chairman on Mar 2 with new comp terms
Kevin Sayer returns from temporary leave effective March 2, 2026, resuming Executive Chairman role.
Dexcom Q4 revenue $1.26B (+13% YoY); GAAP EPS $0.68; FY2026 guidance $5.16-5.25B
GAAP operating income $323M (25.6% margin), up 860bps YoY; Non-GAAP op income $331.5M.
Dexcom Q4 revenue $1.26B beats high end; FY2026 outlook $5.16-5.25B; new CEO Jake Leach
Q4 total revenue ~$1.260B (+13% YoY), US $892M (+11%), Intl $368M (+18%).
DexCom appoints Jacob Leach as CEO effective Jan 1, 2026; sets compensation terms
Jacob S. Leach promoted to CEO from President/COO; effective Jan 1, 2026, succeeding Kevin Sayer on medical leave.
Dexcom Q3 revenue $1.209B (+22% YoY); raises FY 2025 revenue guidance to $4.63-4.65B
GAAP EPS $0.70 vs $0.34 YoY; non-GAAP EPS $0.61 vs $0.45 YoY.
DexCom CEO Kevin Sayer takes temporary medical leave; Jacob Leach appointed interim CEO
Kevin R. Sayer, CEO and Chairman, takes temporary medical leave effective Sept 14, 2025.
Revenue $1.157B (+15% YoY); GAAP EPS $0.45, non-GAAP EPS $0.48.
DexCom Q1 revenue $1.04B (+12% YoY); guides FY25 gross margin ~62% (down); announces $750M buyback
GAAP net income $105.4M ($0.27 diluted EPS) vs $146.4M ($0.36) YoY; non-GAAP EPS $0.32 flat.
DexCom receives FDA warning letter for manufacturing deficiencies; reaffirms FY2025 revenue guidance
FDA warning letter cites non-conformities in manufacturing processes and quality systems at San Diego and Mesa facilities.
Dexcom Q4 revenue $1.114B (+8% YoY); GAAP EPS $0.38; FY2025 guidance $4.6B
Q4 revenue $1.114B (+8% YoY); U.S. +4%, international +17% reported.
Dexcom reports preliminary Q4 revenue $1.113B (+8% YoY); guides 2025 revenue $4.60B (+14%)
Q4 2024 preliminary revenue at least $1.113B, up 8% YoY; US revenue $803M (+4%), international $310M (+17%).
DexCom and Abbott settle global patent litigation, enter royalty-free cross-license
DexCom and Abbott signed a settlement and patent cross-license agreement on Dec 20, 2024.
Dexcom Q3 revenue $994M (+2%); reiterates FY24 guidance; CCO retiring
Revenue $994.2M (+2% reported, +3% organic); U.S. down 2%, international up 12%.
Dexcom Q2 rev $1.004B (+15%); GAAP EPS $0.35; lowers FY rev guidance to $4.00-4.05B
Revenue $1.004B (+15% YoY); US +19%, intl +7% reported; organic growth 16%.
Dexcom Q1 revenue up 24% to $921M; GAAP EPS $0.36; updates FY guidance to $4.2-4.35B
Revenue $921M (+24% YoY); GAAP net income $146.4M ($0.36 EPS) vs $48.6M ($0.12) in Q1 2023.
On May 9, 2025, Jacob S. Leach was promoted to President and Chief Operating Officer of DexCom, Inc. (the “Company”) effective immediately.
On May 1, 2025, Karen Dahut, a director of DexCom, Inc. (the “Company”), resigned from the Board of Directors (the “Board”) of the Company and all committees thereof effective May 8, 2025.
On March 6, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) increased the size of the Board to eleven directors and appointed Renée Galá as a director effective immediately.
Max materiality 0.88 · Median 0.65 · Most common event earnings